The United Laboratories International Holdings Limited (3933.HK)
HKD 12.68
(-0.94%)
HKD 12.68
(-0.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.75 Billion CNY | -20.96% |
| 2022 | -2.28 Billion CNY | -53.15% |
| 2021 | -1.48 Billion CNY | -89.56% |
| 2020 | -785.46 Million CNY | -142.84% |
| 2019 | 1.83 Billion CNY | -31.44% |
| 2018 | 2.67 Billion CNY | -18.06% |
| 2017 | 3.26 Billion CNY | -10.78% |
| 2016 | 3.65 Billion CNY | -16.5% |
| 2015 | 4.38 Billion CNY | -14.6% |
| 2014 | 5.12 Billion CNY | -1.05% |
| 2013 | 5.18 Billion CNY | 9.44% |
| 2012 | 4.73 Billion CNY | 134.88% |
| 2011 | 2.01 Billion CNY | 25.45% |
| 2010 | 1.6 Billion CNY | -9.3% |
| 2009 | 1.77 Billion CNY | 25.01% |
| 2008 | 1.41 Billion CNY | 55.18% |
| 2007 | 913.59 Million CNY | -33.32% |
| 2006 | 1.37 Billion CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.11 Billion CNY | 0.0% |
| 2023 Q2 | -3.21 Billion CNY | 0.0% |
| 2023 Q4 | -2.75 Billion CNY | 0.0% |
| 2023 FY | -2.75 Billion CNY | -20.96% |
| 2022 Q4 | -2.28 Billion CNY | 0.0% |
| 2022 FY | -2.28 Billion CNY | -53.15% |
| 2022 Q2 | -1.89 Billion CNY | 0.0% |
| 2021 Q2 | -1.27 Billion CNY | 0.0% |
| 2021 FY | -1.48 Billion CNY | -89.56% |
| 2021 Q4 | -1.48 Billion CNY | 0.0% |
| 2020 Q2 | 187.94 Million CNY | 0.0% |
| 2020 Q4 | -785.46 Million CNY | 0.0% |
| 2020 FY | -785.46 Million CNY | -142.84% |
| 2019 Q2 | 1.83 Billion CNY | 0.0% |
| 2019 FY | 1.83 Billion CNY | -31.44% |
| 2019 Q4 | 1.83 Billion CNY | 0.0% |
| 2018 Q2 | 3.22 Billion CNY | 0.0% |
| 2018 Q4 | 2.67 Billion CNY | 0.0% |
| 2018 FY | 2.67 Billion CNY | -18.06% |
| 2017 FY | 3.26 Billion CNY | -10.78% |
| 2017 Q4 | 3.26 Billion CNY | 0.0% |
| 2017 Q2 | 4.07 Billion CNY | 0.0% |
| 2016 Q4 | 3.65 Billion CNY | 0.0% |
| 2016 FY | 3.65 Billion CNY | -16.5% |
| 2016 Q2 | 4.37 Billion CNY | 0.0% |
| 2015 FY | 4.38 Billion CNY | -14.6% |
| 2015 Q2 | 4.93 Billion CNY | 0.0% |
| 2015 Q4 | 4.38 Billion CNY | 0.0% |
| 2014 Q2 | 5.26 Billion CNY | 0.0% |
| 2014 Q4 | 5.12 Billion CNY | 0.0% |
| 2014 FY | 5.12 Billion CNY | -1.05% |
| 2013 Q2 | 5.4 Billion CNY | 0.0% |
| 2013 FY | 5.18 Billion CNY | 9.44% |
| 2013 Q4 | 5.18 Billion CNY | 0.0% |
| 2012 Q2 | 2.52 Billion CNY | 0.0% |
| 2012 Q4 | 4.73 Billion CNY | 0.0% |
| 2012 FY | 4.73 Billion CNY | 134.88% |
| 2011 Q4 | 2.01 Billion CNY | 0.0% |
| 2011 Q2 | 1.99 Billion CNY | 0.0% |
| 2011 FY | 2.01 Billion CNY | 25.45% |
| 2010 Q4 | 1.6 Billion CNY | 0.0% |
| 2010 FY | 1.6 Billion CNY | -9.3% |
| 2010 Q2 | 1.98 Billion CNY | 0.0% |
| 2009 Q4 | 1.77 Billion CNY | 0.0% |
| 2009 FY | 1.77 Billion CNY | 25.01% |
| 2008 FY | 1.41 Billion CNY | 55.18% |
| 2007 FY | 913.59 Million CNY | -33.32% |
| 2006 FY | 1.37 Billion CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -966.205% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 235.753% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 46504.862% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 1014.751% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -14388.418% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 9012.708% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -1158.184% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 1176.773% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 830.582% |
| SSY Group Limited | 1.71 Billion HKD | 260.973% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -37179.43% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 917.416% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 105.411% |